AngioDynamics, Inc. $ANGO Shares Purchased by Armistice Capital LLC

Armistice Capital LLC lifted its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 3.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,700,000 shares of the medical instruments supplier’s stock after purchasing an additional 64,000 shares during the period. Armistice Capital LLC owned about 4.12% of AngioDynamics worth $21,828,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Farther Finance Advisors LLC lifted its stake in shares of AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 1,199 shares during the period. Washington Trust Advisors Inc. acquired a new position in shares of AngioDynamics in the 3rd quarter valued at $27,000. Kemnay Advisory Services Inc. acquired a new position in shares of AngioDynamics in the 4th quarter valued at $27,000. State of Wyoming acquired a new position in shares of AngioDynamics in the 2nd quarter valued at $31,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of AngioDynamics by 329.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 3,213 shares during the period. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Stock Down 3.4%

Shares of NASDAQ ANGO opened at $11.74 on Thursday. The firm has a 50-day simple moving average of $11.21 and a 200-day simple moving average of $11.38. The stock has a market capitalization of $485.10 million, a price-to-earnings ratio of -15.65 and a beta of 0.38. AngioDynamics, Inc. has a 52 week low of $8.36 and a 52 week high of $13.99.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. The firm had revenue of $78.42 million during the quarter, compared to analyst estimates of $76.77 million. As a group, equities research analysts expect that AngioDynamics, Inc. will post -0.19 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ANGO. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Canaccord Genuity Group reduced their price objective on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Zacks Research cut shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, AngioDynamics currently has a consensus rating of “Moderate Buy” and an average target price of $18.67.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.